IS C-PEPTIDE A RECIPIENT SELECTION CRITERION?
C. Dieterle, H. Schiffl, R. Landgraf Department of Internal Medicine, Klinikum Innenstadt, University of Munich, Germany Background and Aims: Incidence and prevalence of secondary complications in patients with type 2 diabetes (DM 2) are increasing steadily. Thirty to 50% of all patients with endstage renal disease entering chronic dialysis are DM 2. Recently manifestation of type 2 diabetes has been observed in young populations and therefore many patients will suffer from diabetic complications much earlier in life. Since the long-term survival of pancreatic grafts in patients with type 1 diabetes are excellent (one-year graft survival 80-90%) Eurotransplant started to consider DM 2 for simultaneous pancreas/kidney transplantation, however excluding those patients with basal C-peptide < 0.8 ng/ml and glucagon-stimulated values three times above baseline. Methods: In order to select type 2 diabetic patients for a pancreas/kidney transplantation programme we analyzed C-peptide in 25 no
